Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Hepatitis C; Liver Fibrosis
Intervention: peginterferon alfa-2b (SCH 54031) (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp.
Summary
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no
treatment for the prevention of fibrosis progression in adult participants with moderate to
severe liver fibrosis secondary to chronic hepatitis C, who failed PEG-Intron plus Rebetol
treatment in protocol P02370 (NCT00039871).
Clinical Details
Official title: PEG-Intron(TM) Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adult Subjects With Chronic Hepatitis C With Hepatic Fibrosis (METAVIR Fibrosis Score of F2 or F3), Who Failed Therapy With PEG-Intron Plus REBETOL(R) (in Protocol No. P02370)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).
Secondary outcome: Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale) The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline Mean Change in the METAVIR Activity Score (Using a Continuous Scale) Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age at entry in study P02370 (NCT00039871) 18-65 years;
- Nonresponder to PEG-Intron plus Rebetol in study P02370
Exclusion Criteria:
- Participants who did not participate in the P02370 study.
- Any medical condition, including but not limited to decompensated liver disease,
malignancy or substance abuse, that developed during the P02370 study which could
interfere with the participant's participation in and completion of this study.
Locations and Contacts
Additional Information
Starting date: October 2002
Last updated: October 28, 2014
|